Clinical Evidence and Formulation Value of an NVTIA Quercetin-Eucalyptus Oil Layered Respiratory Support System

Abstract

Background: Respiratory-support compositions that aim to reduce cough, sputum burden, airway irritation, and post-inflammatory discomfort often fail in practice because volatile ingredients are lost during storage, enzyme components are inactivated in gastric acid, and multi-ingredient formulas disperse poorly in vivo. Methods: We examined a seven-ingredient NVTIA composition containing quercetin, eucalyptus oil, bromelain, dihydromyricetin, perillaldehyde, icariin, and ultra-low-molecular-weight sodium hyaluronate. We summarized the formulation-level dataset associated with this composition and then searched public clinical literature through March 2026 for randomized or controlled human studies and systematic reviews relevant to quercetin, cineole/eucalyptus, bromelain, hyaluronan, and Perilla-derived respiratory or airway-related outcomes. Results: The formulation-level dataset showed bromelain activity retention of 98.1%-98.5% after 2 h in simulated gastric-acid conditions versus 6.8% in a simple comparator, and 6-month total active retention of 95.8%-96.3% at 25 °C versus 32.5% in comparator material. Among public human studies, cineole showed the strongest direct respiratory signal: symptom scores improved significantly in acute rhinosinusitis and acute bronchitis, and 6-month concomitant therapy reduced COPD exacerbation burden while improving asthma-related multi-criteria outcomes. Quercetin was safely tolerated up to 2000 mg/day in COPD, and a later pilot phase II study reported reductions in inflammatory and oxidative stress markers, but broad symptom efficacy remains inconsistent across populations. Perilla-derived clinical evidence supported improvement in allergic rhinoconjunctivitis, especially when paired with quercetin in pediatric preventive use. Bromelain evidence in sinus disease remained suggestive but methodologically uneven, and inhaled hyaluronan studies supported mucociliary and airway-support concepts without directly validating oral sodium hyaluronate. Conclusions: Taken together, we believe the layered delivery concept is formulation-rational and clinically plausible, but no completed human trial currently verifies the full seven-ingredient finished composition itself. A registered randomized controlled trial of the final product remains necessary.